新型FAPI二聚体[68Ga]Ga-LNC1013的临床转化研究
本研究设计合成三种新型FAPI同源二聚体,经临床前筛选出先导化合物[68Ga]Ga-LNC1013,并在7例消化道肿瘤患者中开展初步临床PET显像。结果显示该化合物有效剂量为8.24E-03 mSv/MBq,肿瘤摄取持久且靶本比良好,在胰腺癌和食管癌检测中优于18F-FDG PET。作者认为二聚化是改善FAPI肿瘤摄取与滞留的有效策略,LNC1013未来有望用于FAP阳性肿瘤的放射性配体治疗。
要点
- 三种新型FAPI同源二聚体在体外和体内均显示高结合亲和力与特异性,[68Ga]Ga-LNC1013肿瘤滞留至少4小时且摄取高于其他二聚体和单体。
- 初步临床研究中[68Ga]Ga-LNC1013有效剂量为8.24E-03 mSv/MBq,7例消化道肿瘤患者显像显示明显肿瘤摄取和良好靶本对比。
- [68Ga]Ga-LNC1013 PET在检测胰腺癌和食管癌方面优于18F-FDG PET,1至4小时肿瘤摄取持续较高,而[68Ga]Ga-FAPI-46病灶SUVmax随时间下降。
核心结论
- 二聚化是产生具有良好肿瘤摄取、长肿瘤滞留和优于单体显像对比度的FAPI衍生物的有效策略。
- [68Ga]Ga-LNC1013不含哌嗪基团,诊断潜力优于[68Ga]Ga-FAPI-46和18F-FDG,提示LNC1013未来可用于FAP阳性肿瘤的放射性配体治疗。
研究设计与样本
- 设计合成三种以不同连接臂连接两个喹啉基FAPI的新型FAPI二聚体,并与单体FAPI-04和FAPI-46进行体外结合亲和力及临床前小动物PET显像比较。
- 筛选出的先导化合物[68Ga]Ga-LNC1013在7例消化道肿瘤患者中开展初步临床PET显像研究。
主要发现
- 三种新合成的FAPI同源二聚体在体外和体内均具有高结合亲和力和特异性。
- 小动物PET显像和生物分布研究显示[68Ga]Ga-LNC1013肿瘤滞留至少4小时,且摄取高于其他两种二聚体和单体对应物。
- 初步临床PET显像中7例患者入组,[68Ga]Ga-LNC1013有效剂量为8.24E-03 mSv/MBq,人体生物分布显示明显肿瘤摄取和良好靶本对比。
- [68Ga]Ga-LNC1013 PET显像在捕获原发和转移病灶方面有潜力,在检测胰腺癌和食管癌方面优于18F-FDG PET。
- [68Ga]Ga-FAPI-46病灶SUVmax随时间下降,而[68Ga]Ga-LNC1013在注射后1至4小时显示持续高肿瘤摄取。
关键数值与推荐
- [68Ga]Ga-LNC1013的有效剂量为8.24E-03 mSv/MBq。
- [68Ga]Ga-LNC1013肿瘤滞留至少4小时,摄取高于其他两种二聚体和单体对应物。
- [68Ga]Ga-LNC1013在检测胰腺癌和食管癌方面优于18F-FDG PET。
- [68Ga]Ga-FAPI-46病灶SUVmax随时间下降,[68Ga]Ga-LNC1013在注射后1至4小时持续高肿瘤摄取。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Fibroblast activation protein (FAP) has emerged as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of suitably radiolabeled FAP inhibitors (FAPIs), this study presents the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging study were conducted to screen the lead compound with the potential for radionuclide therapy. METHODS: Three new FAPI dimers were synthesized by linking two quinoline-based FAPIs with different spacers. The in vitro binding affinity and preclinical small animal PET imaging of the compounds were compared with their monomeric counterparts, FAPI-04 and FAPI-46. The lead compound, [68Ga]Ga -LNC1013, was then evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer. RESULTS: The three newly synthesized FAPI homodimers had high binding affinity and specificity in vitro and in vivo. Small animal PET imaging and biodistribution studies showed that [68Ga]Ga-LNC1013 had persistent tumor retention for at least 4 h, also higher uptake than the other two dimers and the monomer counterparts, making it the lead compound to enter clinical investigation. In the pilot clinical PET imaging study, seven patients were enrolled. The effective dose of [68Ga]Ga-LNC1013 was 8.24E-03 mSv/MBq. The human biodistribution of [68Ga]Ga-LNC1013 demonstrated prominent tumor uptake and good tumor-to-background contrast. [68Ga]Ga-LNC1013 PET imaging showed potential in capturing primary and metastatic lesions and outperforming 18F-FDG PET in detecting pancreatic and esophageal cancers. The SUVmax for lesions with [68Ga]Ga-FAPI-46 decreased over time, whereas [68Ga]Ga-LNC1013 exhibited persistently high tumor uptake from 1 to 4 h post-injection. CONCLUSION: Dimerization is an effective strategy to produce FAPI derivatives with favorable tumor uptake, long tumor retention, and imaging contrast over its monomeric counterpart. We demonstrated that [68Ga]Ga-LNC1013, the lead compound without any piperazine moiety, had superior diagnostic potential over [68Ga]Ga-FAPI-46 and 18F-FDG, suggesting the future potential of LNC1013 for radioligand therapy of FAP-positive cancers.
引用
- Tan Y, Li J, Zhao T, et al. Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013. Eur J Nucl Med Mol Imaging. 2024. PMID: 38561515. doi:10.1007/s00259-024-06703-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。